Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Adverse effects · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects compared with tacrolimus 0.1% (moderate certainty).
1 finding from 1 review
Adverse effects · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.1% changes adverse effects compared with ciclosporin (very low certainty).
1 finding from 1 review
Common adverse effects · people with mycosis fungoides
1 finding from 1 review
Common adverse effects · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ burning compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ itching · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ itching compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ 6 weeks · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.1% changes adverse effects ‐ 6 weeks compared with pimecrolimus 1% (very low certainty).
1 finding from 1 review
Adverse effects ‐ erythema · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ erythema compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects (non‐serious) · participants with hidradenitis suppurativa
Topical clindamycin showed no clear difference in adverse effects (non‐serious) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects (4 to 6 weeks) · eczema
1 finding from 1 review
Adverse effects (4 to 8 weeks) · eczema
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found